Share
    NEW SEARCH RETURN TO SEARCH RESULTS
Number: GOG 0241 Principal Investigator: Mutch, David
Title: A GCIG Intergroup Multicenter Phase III Trial of Open Label Carboplatin and Paclitaxel +/- NCI Supplied Agent: Bevacizumab (NSC #704865, IND #7921) Compared with Oxaliplatin and Capecitabine +/- Bevacizumab as First Line Chemotherapy in Patients with Mucinous Epithelial Ovarian Cancer or Fallopian Tube Cancer
Phase: III Disease Site: Multiple Sites
Participating Site(s):
 
 
Contact: 800-600-3606 or info@ccadmin.wustl.edu

Description:
The purpose of this study is to compare the effects of several different treatments to find out which works better to control your cancer. In this study, you will receive one of the following treatments: 1) oxaliplatin and capecitabine; 2) standard treatment with carboplatin and paclitaxel; 3) the combination of oxaliplatin, capecitabine and bevacizumab; or 4) the combination of carboplatin, paclitaxel and bevacizumab. The treatment assigned will be based on a process called randomization.
 
More Information:
Internal Protocol Documents (requires Siteman administrative database password)